{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT01989429: Phase 3 Interventional Completed Plaque Psoriasis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pefcalcitol (previously known as M518101), an analog of vitamin D3 (VD3), is an antipsoriatic drug candidate that is designed to achieve much higher pharmacological effects, such as keratinocyte differentiation. This drug is a phosphodiesterase inhibitor and is being developed as a topical ointment formulation. Pefcalcitol was involved in phase III clinical trials in the USA and in Japan in subjects with plaque psoriasis and with palmoplantar keratoderma. In addition, it participated in phase II clinical trial for the warts treatment.
Status:
Investigational
Source:
NCT03860506: Phase 1 Interventional Completed Healthy
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
PSI-697 is a quinoline derivative patented by Wyeth, John, and Brother Ltd. as a selectin inhibitor useful for the treatment of acute coronary syndromes. Surface expression of P-selectin on activated platelets induces the formation of platelet-monocyte aggregates and promotes vascular inflammation and thrombosis. In cell-based assays, PSI-697 dose-dependently inhibits the binding of human P-selectin to human P-selectin glycoprotein ligand-1. In preclinical trials, PSI-697, promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis. Animals receiving PSI-697 demonstrated significantly increased plasma D-dimer levels versus low-molecular-weight-heparin and control animals six hours post thrombus induction. Unfortunately, in clinical trials, PSI-697 did not inhibit basal or stimulated platelet-monocyte aggregate formation in humans
Status:
Investigational
Source:
NCT04102995: Phase 2 Interventional Completed Menstrual Migraine
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Sepranolone (UC1010) is a GABA-A modulating steroid antagonist (GAMSA) and does not antagonize the effect of GABA itself or other GABAA agonists like benzodiazepines and barbiturates. The interaction of neuroactive steroids (i.e., allopregnanolone and Sepranolone) with GABA-A receptor is particularly important in mood disorders. For example, allopregnanolone administration decreased saccadic eye velocity in healthy female volunteers and induced sedation and these effects were diminished by simultaneous sepranolone administration. Thus, allopregnanolone effects are antagonized by its isomer sepranolone. UC1010 reduces symptom severity and impairment significantly more efficiently than placebo in women with a well-defined, pure premenstrual dysphoric disorder. No severe adverse events were reported during the UC1010 treatment and safety parameters (vital signs and blood chemistry) remained normal during the study. It was revealed also that increases in ring A-reduced progesterone metabolites, particularly Sepranolone, are associated with chronic fatigue syndrome.
Status:
Investigational
Source:
NCT02863952: Not Applicable Interventional Unknown status Coronary Artery Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Zinc telluride is a binary chemical compound with the formula ZnTe. Zinc telluride (ZnTe) is a wide-band-gap II–VI semiconductor (E g=2.25 eV at 300 K) crystallizing in the cubic, zinc-blende structure. This material is promising for application as a purely green light-emitting diode. As Zinc telluride can be easily doped, and for this reason it is one of the more common semiconducting materials used in optoelectronics. Zinc telluride finds applications in the following:
LEDs and laser diodes
Solar cells
Tetrahertz imaging
Electro-optic detector
Holographic interferometry
Laser optical phase conjugation devices.
Gold–zinc telluride (Au–ZnTe) core–shell nanoparticles were synthesized to support surface modifications for enhanced drug delivery in cancer therapeutics.
Status:
Investigational
Source:
NCT00555074: Phase 2 Interventional Completed Obesity
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tungstic acid is a fairly strong acid, it catalyzes the oxidation by hydrogen peroxide of alkenes to the corresponding epoxides. Tungstic acid is widely used in the production of tungsten metal, alloys, and is used as a mordant for textiles and plastics. Tungstic acid has been reported to
rapidly precipitate the quaternary ammonium cations in cholinergic nerve terminals, such as ACh or choline. Also, tungsten dietary supplementation has successfully
been used to reduce xanthine oxide (XO) activity,
resulting in decreased gastrointestinal (GI) mucosal damage because of lowered XO activity. Tungstic acid has been shown to effectively antagonize stress-induced gastric ulcers, possibly by decreasing motility and mass cell degranulation. Tungstic acid gel has been used as an epileptogenic agent since 1960. Epilepsy produced by this agent is characterized by good localization, short latency and limited duration. It is effective in cerebral cortex, brain stem and spinal cord.
Status:
Investigational
Source:
NCT00506012: Phase 2 Interventional Terminated Myoclonus
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
T-2000 is an oxopyrimidine derivative patented by Taro Pharmaceutical Industries Ltd. as a tranquilizing agent. T-2000 acts as a modulator of GABA A receptor with well-documented anticonvulsant activity and little sedation in animal models. In vitro, equimolar concentrations of T-2000 and phenobarbital produce equivalent enhancement of GABA-evoked chloride currents. Unfortunately, in clinical trials T-2000 failed to demonstrate efficacy in older patients with essential tremor. Moreover, daily administration of T2000 resulted in higher total blood barbiturate levels, likely accounting for the poor tolerability.
Status:
Investigational
Source:
NCT02499497: Phase 2 Interventional Completed Prostate Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LY2452473 is a selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activity. Upon oral administration, LY2452473 acts as an agonist in select tissues and organs, including skeletal muscle, bone and the penis, thereby binding to and activating androgen receptor (AR) while acting as an antagonist in the prostate, thereby blocking AR activation and AR-mediated cellular proliferation. This may improve muscle mass and strength, bone formation, and erectile dysfunction while not stimulating growth of the prostate. Eli Lilly was developing LY 2452473/tadalafil combination for the treatment of erectile dysfunction. In addition, Eli Lilly is studying the use of a targeted LY 2452473 therapy, as a possible improvement in quality of life for prostate cancer patients who have undergone radical prostatectomy.
Status:
Investigational
Source:
NCT04173065: Phase 2 Interventional Completed NASH - Nonalcoholic Steatohepatitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MB-07811 (VK-2809) is the liver-activated prodrug of a phosphonate-containing thyroid hormone receptor beta agonist MB-07344. In animal studies, it showed potent lipid and cholesterol lowering activity. Viking Therapeutics is developing MB-07811 hypercholesterolaemia and non-alcoholic fatty liver disease.
Status:
Investigational
Source:
NCT00264433: Phase 2 Interventional Completed Neoplasms
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Exherin is a small, cyclic pentapeptide vascular-targeting agent with potential antineoplastic and antiangiogenic activities. ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. In murine melanoma xenografts, ADH-1 in combination with melphalan significantly reduced tumor growth up to 30-fold over melphalan alone. ADH-1 enhancement of response to melphalan was associated with increased formation of DNA adducts, increased apoptosis, and intracellular signaling changes. In a pilot study (phase I trial), ADH-1 intravenous pretreatment before chemotherapy in metastatic melanoma completely destroyed tumors in half of patients
Status:
Investigational
Source:
NCT00258622: Phase 2 Interventional Completed Pain
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
